FI865159A - Kompositioner som innehaoller en stabiliserad aktivator foer maenniskans vaevnadsplasminogen. - Google Patents

Kompositioner som innehaoller en stabiliserad aktivator foer maenniskans vaevnadsplasminogen. Download PDF

Info

Publication number
FI865159A
FI865159A FI865159A FI865159A FI865159A FI 865159 A FI865159 A FI 865159A FI 865159 A FI865159 A FI 865159A FI 865159 A FI865159 A FI 865159A FI 865159 A FI865159 A FI 865159A
Authority
FI
Finland
Prior art keywords
stabilizers
splasminogen
mainness
activators
composition
Prior art date
Application number
FI865159A
Other languages
English (en)
Other versions
FI88873B (fi
FI88873C (fi
FI865159A0 (fi
Inventor
William Franklin Bennett
Stuart Elliot Builder
Larry Alan Gatlin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25205495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI865159(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI865159A0 publication Critical patent/FI865159A0/fi
Publication of FI865159A publication Critical patent/FI865159A/fi
Publication of FI88873B publication Critical patent/FI88873B/fi
Application granted granted Critical
Publication of FI88873C publication Critical patent/FI88873C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
FI865159A 1985-12-17 1986-12-17 Foerfarande foer framstaellning av kompositioner som innehaoller stabiliserad human vaevnadsplasminogenaktivator FI88873C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/811,081 US4777043A (en) 1985-12-17 1985-12-17 Stabilized human tissue plasminogen activator compositions
US81108185 1985-12-17

Publications (4)

Publication Number Publication Date
FI865159A0 FI865159A0 (fi) 1986-12-17
FI865159A true FI865159A (fi) 1987-06-18
FI88873B FI88873B (fi) 1993-04-15
FI88873C FI88873C (fi) 1993-07-26

Family

ID=25205495

Family Applications (1)

Application Number Title Priority Date Filing Date
FI865159A FI88873C (fi) 1985-12-17 1986-12-17 Foerfarande foer framstaellning av kompositioner som innehaoller stabiliserad human vaevnadsplasminogenaktivator

Country Status (23)

Country Link
US (2) US4777043A (fi)
EP (1) EP0228862B1 (fi)
JP (2) JPH0714886B2 (fi)
KR (1) KR950010322B1 (fi)
AT (1) ATE79273T1 (fi)
AU (1) AU600246B2 (fi)
DD (1) DD255477A5 (fi)
DE (2) DE3642960A1 (fi)
DK (1) DK174203B1 (fi)
ES (1) ES2044840T3 (fi)
FI (1) FI88873C (fi)
FR (1) FR2591485B1 (fi)
GB (1) GB2184354B (fi)
GR (1) GR3006078T3 (fi)
HU (1) HU200101B (fi)
IE (1) IE59060B1 (fi)
IL (1) IL80904A (fi)
MY (1) MY102185A (fi)
NO (1) NO168988C (fi)
NZ (1) NZ218612A (fi)
PH (1) PH24716A (fi)
PT (1) PT83933B (fi)
ZA (1) ZA869457B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1267602A (en) * 1985-09-10 1990-04-10 Fumio Kakimoto Composition containing tissue plasminogen activator
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
JP2708749B2 (ja) 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
ES2045167T5 (es) * 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
DE19606551C2 (de) * 1996-02-22 2000-06-08 Basotherm Gmbh rt-PA zur Prävention des Nachstars nach Kataraktoperation
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
WO2001012653A1 (en) * 1999-08-17 2001-02-22 Novo Nordisk A/S Stabilisation of freeze-dried cake
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
KR100649043B1 (ko) * 1999-11-04 2006-11-27 제넨테크, 인크. 플라스미노겐 활성화제에 대한 역상 고성능 액체크로마토그래피 분석법
EP1273306A4 (en) * 2000-03-31 2005-06-22 Kirin Brewery POWDER PREPARATION INTENDED FOR MUCOUS MEMBRANES COMPRISING A POLYMERIC MEDICAMENT HAVING IMPROVED STORAGE STABILITY
KR20040062535A (ko) * 2001-09-07 2004-07-07 글로벌 바이오텍 인코포레이티드 인간 조직 유로키나아제형 플라스미노겐 활성화제 배합물
US20110179558A1 (en) * 2009-07-29 2011-07-28 International Enviroguard Systems, Inc. Breathable Protective Fabric and Garment
US20140274873A1 (en) * 2013-03-14 2014-09-18 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98833C (da) * 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
DE3273732D1 (en) * 1982-12-30 1986-11-20 Kowa Co Method of producing a tissue plasminogen activator and composition comprising same
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
AU596356B2 (en) * 1985-04-22 1990-05-03 Genentech Inc. Novel human tissue plasminogen activator mutants
BE904831A (fr) * 1985-05-28 1986-11-27 Wellcome Found Composition d'activateur tissulaire du plasminogene.
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
CA1267602A (en) * 1985-09-10 1990-04-10 Fumio Kakimoto Composition containing tissue plasminogen activator
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
JPS62283932A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤

Also Published As

Publication number Publication date
NO865079D0 (no) 1986-12-16
JPS62164632A (ja) 1987-07-21
HU200101B (en) 1990-04-28
NZ218612A (en) 1989-07-27
ZA869457B (en) 1988-08-31
FR2591485B1 (fr) 1989-07-28
NO168988B (no) 1992-01-20
IL80904A0 (en) 1987-03-31
EP0228862A2 (en) 1987-07-15
DK174203B1 (da) 2002-09-16
FR2591485A1 (fr) 1987-06-19
PT83933A (en) 1987-01-01
PH24716A (en) 1990-10-01
NO865079L (no) 1987-06-18
DK605786A (da) 1987-06-18
FI88873B (fi) 1993-04-15
DD255477A5 (de) 1988-04-06
KR870005647A (ko) 1987-07-06
DE3686410D1 (de) 1992-09-17
MY102185A (en) 1992-04-30
KR950010322B1 (ko) 1995-09-14
US4777043A (en) 1988-10-11
PT83933B (pt) 1989-01-17
GB8629981D0 (en) 1987-01-28
US4908205A (en) 1990-03-13
IL80904A (en) 1992-01-15
GB2184354B (en) 1990-04-11
AU6661086A (en) 1987-06-18
ATE79273T1 (de) 1992-08-15
ES2044840T3 (es) 1994-01-16
NO168988C (no) 1992-04-29
EP0228862B1 (en) 1992-08-12
FI88873C (fi) 1993-07-26
GB2184354A (en) 1987-06-24
JPH0714886B2 (ja) 1995-02-22
HUT42955A (en) 1987-09-28
IE863279L (en) 1987-06-17
DE3686410T2 (de) 1993-02-18
AU600246B2 (en) 1990-08-09
DE3642960A1 (de) 1987-06-19
JPH07173076A (ja) 1995-07-11
GR3006078T3 (fi) 1993-06-21
DK605786D0 (da) 1986-12-16
IE59060B1 (en) 1993-12-15
EP0228862A3 (en) 1988-09-28
FI865159A0 (fi) 1986-12-17

Similar Documents

Publication Publication Date Title
FI865159A0 (fi) Kompositioner som innehaoller en stabiliserad aktivator foer maenniskans vaevnadsplasminogen.
IT1226726B (it) Composti attivi come inibitori della biosintesi del colesterolo.
DK302288A (da) Vaevsplasminogenaktivator med modificeret kringledomaene
NO882454L (no) Plasminogen-aktivator.
PT91584A (pt) Processo para a preparacao de uma composicao farmaceutica util para imunossupressao contendo um inibidor-activador de plasminogenio (pai-2)
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
DK305490D0 (da) Vaevsplasminogenaktivator-analoger med forbedret aktivitet
AU1235288A (en) Antidepressant compositions
GR3005231T3 (fi)
TR22867A (tr) Birden fazla aktif bilesen ihtiva eden insektisid terkibi
EP0264017A3 (en) Pharmaceutical compositions having healing activity
ATE33552T1 (de) Dermatologische praeparate.
SE8503513L (sv) Farmaceutiska och kosmetiska kompositioner, vilka som verksam bestandsdel innehaller acetyl-10-triacetoxi-1,8,9-antracen
KR880012237A (ko) 트롬빈 제제의 제조방법
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: GENENTECH, INC.

MA Patent expired